Moderna won FDA approval on August 5 for mFLUSIVA, the first mRNA-based seasonal flu vaccine, marking a major milestone in expanding the mRNA platform beyond COVID-19 to combat influenza in adults 50 and older.
The vaccine, also known as mRNA-1010, showed approximately 27% greater efficacy than standard flu shots in Phase 3 clinical trial results published in May, according to reporting from The BMJ. The approval clears the way for mFLUSIVA to be available in the United States for the 2026-2027 flu season, offering older adults a new immunization option that uses the same mRNA technology that proved successful during the COVID-19 pandemic.
The path to approval was turbulent. The FDA had initially refused to even review Moderna’s application in February 2026, citing concerns about the vaccine’s trial design. The agency reversed course after public outcry, according to reporting from The New York Times, and launched what became a seven-month review process. An FDA advisory panel voted unanimously 9-0 in favor of the vaccine in June, setting the stage for the August approval.
The approval grants full authorization for adults aged 50 to 64 and accelerated approval for adults 65 and older, according to reporting from HC PLive. Moderna expects to have supplies ready ahead of the fall flu season, when vaccination campaigns typically ramp up.
The stock market reaction was mixed. Moderna shares fell 3.4% to $54.35 on August 6, the day after approval, despite rising in premarket trading, according to Barron’s. The decline reflected investor skepticism about near-term revenue impact—analysts noted that meaningful financial benefits from the flu vaccine are not expected until 2027, according to reporting from Dailymotion. Over the prior month, MRNA had shed 31.2% of its value, though the stock remained up 90.8% for the full year 2026.
The global mRNA flu vaccine market represents a significant growth opportunity. The market was valued at $9.43 billion in 2024 and is projected to reach $19.20 billion by 2032, expanding at an annual rate of 9.3%, according to DataBridge Market Research. The mRNA platform offers potential advantages over traditional egg-based flu vaccines, including the ability to more precisely match circulating viral strains and support rapid response to emerging variants, according to reporting from CIDRAP at the University of Minnesota.
Sources
- The BMJ — confirmation of 27% efficacy advantage and approval details
- The New York Times — FDA’s initial refusal and reversal after public outcry
- FDA.gov — official approval date (August 5, 2026) and regulatory pathway
- HC PLive — age-group approval details (50-64 full approval, 65+ accelerated approval)
- Barron’s — stock price reaction on August 6, 2026
- Dailymotion — analyst commentary on revenue timing expectations
- DataBridge Market Research — global mRNA flu vaccine market size and projections
- CIDRAP, University of Minnesota — mRNA platform advantages over traditional vaccines
